CT45A1 and Miyoshi myopathy: Based on the data presented here, it would be worthwhile to consider the novel peptides designed here for Ags overexpressed in MM (MUC1, SLAMF7, BCMA, FcRH5, RHAMM) or cancer testis Ags (CT45, NY-ESO-1) and SEPTIN9 as potential targets for MM immunotherapy.